Journal article
The influence of social support on COPD outcomes mediated by depression
PloS one, Vol.16(3), pp.e0245478-e0245478
03/17/2021
DOI: 10.1371/journal.pone.0245478
PMCID: PMC7968645
PMID: 33730034
Abstract
Background
The purpose of this study was to explore the association between perceived social support and COPD outcomes and to determine whether the associations are mediated by depressive symptoms.
Methods
Subjects with COPD who were enrolled as part of SPIROMICS were included in this analysis. Questionnaires relating to quality of life, symptom burden, and functional status were administered at annual clinic visits for over a 3 year period. In both cross-sectional and longitudinal analyses, we examined the association of social support as measured by the FACIT-F with COPD outcomes. Cross sectional analyses used multivariable linear or logistic regression, adjusting for covariates. For longitudinal analyses, generalized linear mixed models with random intercepts were used. Models were adjusted with and without depressive symptoms and mediation analyses performed.
Results
Of the 1831 subjects with COPD, 1779 completed the FACIT-F questionnaire. In adjusted cross-sectional analysis without depressive symptoms, higher perceived social support was associated with better quality of life, well-being, 6 minute walk distance, and less dyspnea. When also adjusting for depressive symptoms, all associations between social support and COPD outcomes were attenuated and no longer statistically significant. Mediation analysis suggested that depressive symptoms explained the majority (> = 85%) of the association between social support and measured COPD outcomes. Results of the longitudinal analysis were consistent with the cross-sectional analyses. There was no association between social support and odds of exacerbations.
Conclusion
Higher social support was associated with better COPD outcomes across several measures of morbidity including quality of life, respiratory symptoms, and functional status. In addition, these associations were largely attenuated when accounting for depressive symptoms suggesting that the beneficial association of social support with COPD outcomes may be largely mediated by the association between social support and depression.
Details
- Title: Subtitle
- The influence of social support on COPD outcomes mediated by depression
- Creators
- Leonard Turnier - Johns Hopkins MedicineMichelle Eakin - Johns Hopkins MedicineHan Woo - Johns Hopkins MedicineMark Dransfield - University of Alabama at BirminghamTrisha Parekh - University of Alabama at BirminghamJerry A. Krishnan - University of Illinois ChicagoRichard Kanner - University of UtahChristopher B. Cooper - Zhejiang UniversityPrescott G. Woodruff - University of California, San FranciscoRobert Wise - Johns Hopkins MedicineMeiLan K. Han - University of MichiganKarina Romero - Johns Hopkins MedicineLaura M. Paulin - Johns Hopkins MedicineStephen Peters - Atrium Health Wake Forest BaptistBrad Drummond - University of North Carolina at Chapel HillEugene R. Bleecker - Atrium Health Wake Forest BaptistRussell Bowler - National Jewish HealthAlejandro P. Comellas - University of IowaDavid Couper - University of North Carolina at Chapel HillRobert Paine - University of UtahFernando Martinez - College Medical CenterGraham Barr - Columbia University Irving Medical CenterNirupama Putcha - Johns Hopkins MedicineNadia N. Hansel - Johns Hopkins Medicine
- Resource Type
- Journal article
- Publication Details
- PloS one, Vol.16(3), pp.e0245478-e0245478
- DOI
- 10.1371/journal.pone.0245478
- PMID
- 33730034
- PMCID
- PMC7968645
- NLM abbreviation
- PLoS One
- ISSN
- 1932-6203
- eISSN
- 1932-6203
- Publisher
- Public Library Science
- Number of pages
- 12
- Grant note
- Regeneron Pharmaceuticals, Inc.; Regeneron Takeda Pharmaceutical Company; Takeda Pharmaceutical Company Ltd Grifols Therapeutics, Inc. HHSN268200900013C; HHSN268200900014C; HHSN268200900015C; HHSN268200900016C; HHSN268200900017C; HHSN268200900018C; HHSN268200900019C; HHSN268200900020C; U01 HL137880 / NIH/NHLBI; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) Foundation for the NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA ProterixBio Theravance Biopharma Boehringer-Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim P50MD010431 / National Institute on Minority Health and Health Disparities (NIMHD) of the National Institutes of Health COPD Foundation from AstraZeneca/MedImmune; AstraZeneca; Medimmune Mylan Bellerophon Therapeutics GlaxoSmithKline Bayer; Bayer AG Chiesi Farmaceutici S.p.A.; Chiesi Pharmaceuticals Inc R01ES023500 / NIH NIEHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS) Novartis Pharmaceuticals Corporation; Novartis Sunovion Sanofi Ikaria, Inc. Nycomed GmbH Forest Research Institute, Inc.
- Language
- English
- Date published
- 03/17/2021
- Academic Unit
- Pulmonary, Critical Care, and Occupational Medicine; ICTS; Internal Medicine
- Record Identifier
- 9984359874302771
Metrics
14 Record Views